<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_1905-7415.0905.432_s_001_w2aab3b7b4b1b6b1aab1c16b1Aa"><h3>Background</h3><p>Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in the pediatric population. From 25% to 30% of patients with ALL will have a relapse that leads to death when they are teenagers. At Cipto Mangunkusumo Hospital, 40% of 126 pediatric patients with ALL relapsed from 2005 to 2011. A multiple variant of multidrug resistance gene 1 (<italic>MDR1</italic>) is C3435T, which can be used to understand the genetic basis of susceptibility to relapse.</p></sec><sec id="j_1905-7415.0905.432_s_002_w2aab3b7b4b1b6b1aab1c16b2Aa"><h3>Objectives</h3><p>To identify the profile of <italic>MDR1</italic> polymorphism in pediatric Indonesian patients with ALL.</p></sec><sec id="j_1905-7415.0905.432_s_003_w2aab3b7b4b1b6b1aab1c16b3Aa"><h3>Methods</h3><p>We collected data from 44 patients with ALL who attended Cipto Mangunkusumo Hospital between January and June 2014. We investigated a silent C3435T polymorphism in <italic>MDR1</italic> exon 26 with polymerase chain reaction- restriction fragment length polymorphism using <italic>Mbo</italic>I.</p></sec><sec id="j_1905-7415.0905.432_s_004_w2aab3b7b4b1b6b1aab1c16b4Aa"><h3>Results</h3><p>There were 32 male and 12 female patient participants in this study. Eighteen patients were 1–3 years old and 26 were over 3 years. The mean age at 1–3 years was 2.4 ± 0.86, and over 3 years it was 6.3 ± 2.67 years. There were 27 patients with ALL in the standard risk group and 17 in the high risk group. We determined that the 25 samples from patients with ALL in the standard risk group were not digestible (allele T) and the 6 samples from patients with ALL in the high risk group were digestible (allele C).</p></sec><sec id="j_1905-7415.0905.432_s_005_w2aab3b7b4b1b6b1aab1c16b5Aa"><h3>Conclusions</h3><p>The prevalence of the T allele was higher than that of the C allele in pediatric Indonesian patients with ALL.</p></sec></abstract>

BackgroundAcute lymphoblastic leukemia (ALL) is the most prevalent cancer in the pediatric population. From 25% to 30% of patients with ALL will have a relapse that leads to death when they are teenagers. At Cipto Mangunkusumo Hospital, 40% of 126 pediatric patients with ALL relapsed from 2005 to 2011. A multiple variant of multidrug resistance gene 1 (MDR1) is C3435T, which can be used to understand the genetic basis of susceptibility to relapse.ObjectivesTo identify the profile of MDR1 polymorphism in pediatric Indonesian patients with ALL.MethodsWe collected data from 44 patients with ALL who attended Cipto Mangunkusumo Hospital between January and June 2014. We investigated a silent C3435T polymorphism in MDR1 exon 26 with polymerase chain reaction- restriction fragment length polymorphism using MboI.ResultsThere were 32 male and 12 female patient participants in this study. Eighteen patients were 1–3 years old and 26 were over 3 years. The mean age at 1–3 years was 2.4 ± 0.86, and over 3 years it was 6.3 ± 2.67 years. There were 27 patients with ALL in the standard risk group and 17 in the high risk group. We determined that the 25 samples from patients with ALL in the standard risk group were not digestible (allele T) and the 6 samples from patients with ALL in the high risk group were digestible (allele C).ConclusionsThe prevalence of the T allele was higher than that of the C allele in pediatric Indonesian patients with ALL.

Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

BackgroundAcute lymphoblastic leukemia (ALL) is the most prevalent cancer in the pediatric population. From 25% to 30% of patients with ALL will have a relapse...

Variable	n = 44
Age (year)
1-3 years	2.4 ± 0.86
>3 years	6.3 ± 2.67
Age category
1-3 years	18 (41%)
>3 years	26 (59%)
Sex
Male	32 (73%)
Female	12 (27%)
Risk group
Standard	27 (61%)
High	17 (39%)

	ALL patients	Healthy subjects
T allele
Standard risk	25 (57%)	4 (44%)
High risk	12 (27%)
C allele
Standard risk	1 (2%)	5 (56%)
High risk	6 (14%)

Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia

Article Category: Brief communication (Original)

Publié en ligne: 31 janv. 2017

Pages: 625 - 630

DOI: https://doi.org/10.5372/1905-7415.0905.432

Mots clés
Acute lymphoblastic leukemia, ALL, polymorphism, MDR1 gene, P-glycoprotein (P-gp), PCR RFLP

© 2015 Rina Mutiara, Bernadius Agustinus, Christian Badia Sitompul, Amarila Malik, Djajadiman Gatot, Frans D. Suyatna

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Baseline patient characteristics

Frequency of alleles in ALL patients and healthy subjects in the MDR1 study

Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia

Article Category: Brief communication (Original)

Publié en ligne: 31 janv. 2017

Pages: 625 - 630

DOI: https://doi.org/10.5372/1905-7415.0905.432

Mots clésAcute lymphoblastic leukemia, ALL, polymorphism, MDR1 gene, P-glycoprotein (P-gp), PCR RFLP

© 2015 Rina Mutiara, Bernadius Agustinus, Christian Badia Sitompul, Amarila Malik, Djajadiman Gatot, Frans D. Suyatna

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Baseline patient characteristics

Frequency of alleles in ALL patients and healthy subjects in the MDR1 study

Mots clés
Acute lymphoblastic leukemia, ALL, polymorphism, MDR1 gene, P-glycoprotein (P-gp), PCR RFLP